

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IS 00/00028

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12N5/08 A01N1/02 A61K35/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE, LIFESCIENCES, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PENTZ S & HÖRLER H: "A cryopreservative procedure for storing cultivated and uncultivated amniotic fluid cells in liquid nitrogen" JOURNAL OF MEDICAL GENETICS, vol. 17, 1980, pages 472-475, XP000971555 cited in the application the whole document	1-8
X	NIERMEIJER M F ET AL: "Transport and storage of amniotic fluid samples for prenatal diagnosis of metabolic diseases." HUMANGENETIK, vol. 20, no. 2, 1973, pages 175-178, XP000971556 the whole document	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

4 January 2001

Date of mailing of the international search report

15/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT 00/00028

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCAGGIANTE B ET AL: "Impianto di cellule epiteliali amniotiche umane crioconservate in un soggetto affetto da malattia di Niemann-Pick tipo B 'Graft of cryopreserved human amniotic epithelial cells in a subject with type B Niemann-Pick disease! " PEDIATRIA MEDICA E CHIRURGICA, vol. 9, no. 1, January 1987 (1987-01) - February 1987 (1987-02), pages 89-92, XP000971552 page 90 ---	1-8
X	WO 97 35472 A (ADVANCED REPRODUCTION TECHNOLO) 2 October 1997 (1997-10-02) page 9, line 12 -page 10, line 10 ---	1-8
A	US 5 879 937 A (RONCAROLO MARIA-GRAZIA) 9 March 1999 (1999-03-09) ---	
A	EP 0 333 328 A (GENETHICS LTD) 20 September 1989 (1989-09-20) ---	
A	EP 0 815 867 A (SRL INC) 7 January 1998 (1998-01-07) ---	
A	KIND A & COLMAN A: "Therapeutic cloning: Needs and prospects" SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, vol. 17, no. 3, June 1999 (1999-06), pages 1171-1174, XP000971596 ---	
E	WO 00 73421 A (PRESTIDGE PETER D ;WIGGINTON GORDON (GB); GOLDSTEIN ALLAN L (US);) 7 December 2000 (2000-12-07) page 3 -page 6 -----	1-8

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 9

Present claim 9 relates to a compound defined by reference to its origin, namely human amniotic cells. The claim covers all compounds which can be extracted or produced from such source, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for no specific compound. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search was performed for claim 9.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members


International Application No

PC 00/00028

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9735472 A	02-10-1997	US 5897987 A CA 2250084 A EP 0891134 A JP 2000507547 T	27-04-1999 02-10-1997 20-01-1999 20-06-2000
US 5879937 A	09-03-1999	US 5405751 A	11-04-1995
EP 0333328 A	20-09-1989	AT 98111 T AU 3218389 A AU 640609 B CA 1330418 A DE 68911178 D ES 2060750 T WO 8907425 A US 5612028 A	15-12-1993 06-09-1989 02-09-1993 28-06-1994 20-01-1994 01-12-1994 24-08-1989 18-03-1997
EP 0815867 A	07-01-1998	AU 1319797 A WO 9726902 A	20-08-1997 31-07-1997
WO 0073421 A	07-12-2000	NONE	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference ---		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GR00/00028	International filing date (day/month/year) 27/09/2000	Priority date (day/month/year) 29/09/1999	
International Patent Classification (IPC) or national classification and IPC C12N5/08			
Applicant TSAKAS, Spyros et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 9 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application 			
Date of submission of the demand 27/04/2001		Date of completion of this report 29.01.2002	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Fotaki, M Telephone No. +49 89 2399 8709	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GR00/00028

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-11 as originally filed

Claims, No.:

1-9 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GR00/00028

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 2, 6-9 (entirely); 3-5 (partially).

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
 - ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
 - ☒ the claims, or said claims Nos. 2, 6,-8 (entirely); 3-5 (partially) are so inadequately supported by the description that no meaningful opinion could be formed.
 - ☒ no international search report has been established for the said claims Nos. 9.
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- ☐ the written form has not been furnished or does not comply with the standard.
 - ☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GR00/00028

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☐ not complied with for the following reasons:
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☒ all parts.
- ☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	none
	No:	Claims	1 (entirely); 3-5 (partially)
Inventive step (IS)	Yes:	Claims	none
	No:	Claims	1 (entirely); 3-5 (partially)
Industrial applicability (IA)	Yes:	Claims	1 (entirely), 3-5 (partially)
	No:	Claims	

2. Citations and explanations
see separate sheet

III. NON-ESTABLISHMENT OF OPINION

- 1) The present international preliminary examination report is concerned only with the parts of the application for which an international search report has been established (Rule 66.1 (e) PCT). According to the international search report, the subject-matter relating to **Claim 9** has not been searched and thus, no opinion is established for said subject-matter.
- 2) The subject-matter of **Claims 2 (entirely); 3-5 (partially)** is not sufficiently disclosed in the application as filed (Article 5 PCT), and thus, an opinion on novelty, inventive step or industrial applicability cannot be established.

The subject-matter of **Claim 2** relates to amniotic cells isolated from a human embryo-clone which is generated from human body cells.

The application as filed does not disclose a method whereby a human embryo-clone is obtained. The only reference to such method appears on page 9 lines 21-25 where it is stated that an approximately similar technology to the one followed for the generation of a cloned sheep may be applied to produce human embryo-clones. At the time of filing of the present application, the generation of human embryo-clones has not been established because of technical and ethical limitations and the assertions of the Applicant that "with an approximately similar technology human embryo-clones may be produced" appears to be fictitious and unformed.

Subject-matter defined by reference to **Claim 2** . i.e. **Claims 3-5 (partially)**, is not sufficiently disclosed either. Consequently, a meaningful opinion on novelty inventive step and industrial applicability of said cells cannot be established.

Furthermore, the application states that "it is permitted and legitimately and scientifically acceptable nowadays to produce human clone embryos and to store them up to 14 days of age" (p. 9). The present Authority would like to point out that this statement is false. As a general comment on the application statements about generation of human embryo clones (p. 9-11), it appears that the Applicant confuses the embryos produced during human *in vitro* fertilization treatment which

are not clones of either of their parents and animal clones produced through nuclear transfer techniques. The latter methods have not been practised with human material.

The present Authority stresses the fact that methods of cloning of human beings are not only unavailable to the skilled person but also that such methods, particularly if intended for reproductive cloning, are clearly unallowable in several PCT Member States. Products and methods based on cloning of human beings are technically non-existent and they interfere with legal requirements based on ethical grounds. Therefore, even if technical developments of the art permit such methods and products, the allowability of claims directed to such subject-matter, on ethical grounds, is questionable.

- 3) The subject-matter of **Claims 6-8** is not sufficiently disclosed in the application as filed (Article 5 PCT), and thus, an opinion on novelty, inventive step or industrial applicability cannot be established.

Said claims relate to amniotic cells:

- (i) capable of differentiating into cells, tissues, organs,
- (ii) capable of generating cell lines resistant to pathogens, viruses, bacteria,
- (iii) capable of generating differentiated cell lines
- (iv) capable of producing tissues, organs or genetic clones.

Since the application as filed does not explicitly list the technical features of the claimed amniotic cells neither provide methods whereby amniotic cells may rendered capable of any of the above mentioned technical effects, the definition of said amniotic cells is merely based on desired/putative technical features rather than disclosed technical features which are essential in order to perform the invention claimed. An opinion on novelty, inventive step or industrial applicability cannot be established for subject-matter which is not sufficiently disclosed.

IV. UNITY OF INVENTION

- 4) The international search report has been drawn up in respect of the entire international application. However, IPEA finds that the application does not comply with the requirement of unity of invention (Article 34(3) and Rules 13 and 68 PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GR00/00028

The application as filed is considered to lack unity of invention since its subject-matter relates not to one but rather to two separate inventions not linked together by a common underlying inventive concept. The claims and the inventions to which they relate may be grouped as follows:

INVENTION I

Claims 1 (entirely); 3-8 (partially): cryopreserved amniotic cells derived from human amniotic fluid; compositions comprising said cells; the use of said cells in diagnostic or therapeutic methods or in methods of genetic identification.

INVENTION II

Claims 2 (entirely); 3-8 (partially): cryopreserved amniotic cells derived from human body cells after the generation of an embryo-clone from these human body cells; compositions comprising said cells; the use of said cells in diagnostic or therapeutic methods or in methods of genetic identification.

- 5) An international application must relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. Unity of invention is fulfilled only when there is a technical relationship among the inventions involving one or more of the same or corresponding special technical features. Special technical features are such features that define the contribution of the claimed invention over the prior art.

The identified two inventions relate to human amniotic cells which involve the technical feature of "being cryopreserved" as the sole common link. However, this feature cannot be accepted to constitute a special technical feature because it does not define a contribution over the prior art. Human amniotic cells derived from the amniotic fluid or from amnion epithelium are widely-known in the art (see the cited documents, for example,

PENTZ S & HÖRLER H: 'A cryopreservative procedure for storing cultivated and uncultivated amniotic fluid cells in liquid nitrogen' JOURNAL OF MEDICAL GENETICS, vol. 17, 1980, pages 472-475;

NIERMEIJER M F ET AL: 'Transport and storage of amniotic fluid samples for prenatal diagnosis of metabolic diseases.' HUMANGENETIK, vol. 20, no. 2, 1973, pages 175-178;

SCAGGIANTE B ET AL: 'Impianto di cellule epiteliali amniotiche umane crioconservate in un soggetto affetto da malattia di Niemann-Pick tipo B [Graft of

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GR00/00028

cryopreserved human amniotic epithelial cells in a subject with type B Niemann-Pick disease] ' PEDIATRIA MEDICA E CHIRURGICA, vol. 9, no. 1, January 1987 (1987-01) - February 1987 (1987-02), pages 89-92).

- 6) The contributions claimed in the present application which are allegedly made over the prior art are:

- a) cryopreserved human amniotic cells derived from amniotic fluid;
- b) cryopreserved human amniotic cells derived from amniotic tissues of a cloned embryo .

These contributions are not so linked as to form one single inventive concept. Therefore, the IPEA is of the opinion that there is no single unifying inventive concept underlying the entire group of claims of the present Application as required by Rule 13 PCT. However, as a full International Search Report has been established a Preliminary Examination may also be conducted concerning the subject-matter of both inventions. Taking into account the restrictions posed from lack of sufficient disclosure which lead to non-establishment of opinion (see above), the present Authority does not invite the Applicant to pay additional fees (Rule 68.1 PCT).

V. REASONED STATEMENT UNDER RULE 66.2 (a) (ii)

- 7) This preliminary international report has been established considering the priority date 21.04.97 as a valid date. The Applicant is reminded that document: WO 00/73421 published 07.12.00 cited in the international search report may become relevant after consideration of the priority document which is unavailable at present.
- 8) The following documents are referred to:
- D1: PENTZ S & HÖRLER H: 'A cryopreservative procedure for storing cultivated and uncultivated amniotic fluid cells in liquid nitrogen' JOURNAL OF MEDICAL GENETICS, vol. 17, 1980, pages 472-475,
 - D2: NIERMEIJER M F ET AL: 'Transport and storage of amniotic fluid samples for prenatal diagnosis of metabolic diseases.' HUMANGENETIK, vol. 20, no. 2,

1973, pages 175-178,

D3: WO 97 35472 A (ADVANCED REPRODUCTION TECHNOLOGY) 2 October
1997 (1997-10-02)

- 9) Subject-matter of **Claims 1 (entirely); 3-5 (partially)** for which an opinion may be established relates to amniotic cells derived from human amniotic fluid and subjected to cryopreservation method by addition of glycerine, DMSO or polyethylene glycol. The cells are stored frozen at temperature of -196°C and may be used in methods of diagnosis, therapy or genetic identification.
- 10) The subject-matter of **Claim 1** is not novel as required by Article 33(2) PCT. Documents D1-D3 disclose the cryopreservation of human amniotic cells derived from amniotic fluid, thus, rendering the subject-matter of said claim not novel.

Documents D1-D3 disclose the cryopreservation of human amniotic cells through the use of cryopreservative agents such as glycerol (D1, D3), DMSO (D1, D2, D3), polyethylene glycol (D3). Thus, the subject-matter of **Claim 3 (partially)** is not novel.

The subject-matter of **Claims 4, 5 (partially)** relates to the use of cryopreserved amniotic cells for diagnosis or therapy. Documents D1, D2 disclose the use of said cells for diagnosis, while document D3 discloses the use of said cells for medical purposes. Thus, the subject-matter of said claims is not novel.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GR 00/ 00028	International filing date (day/month/year) 27/09/2000	(Earliest) Priority Date (day/month/year) 29/09/1999
Applicant TSAKAS, Spyros et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 14 June 2001 (14.06.01)	
International application No. PCT/GR00/00028	Applicant's or agent's file reference
International filing date (day/month/year) 27 September 2000 (27.09.00)	Priority date (day/month/year) 29 September 1999 (29.09.99)
Applicant TSAKAS, Spyros et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

27 April 2001 (27.04.01)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Claudio Borton Telephone No.: (41-22) 338.83.38
--	---

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23532 A1

- (51) International Patent Classification⁷: C12N 5/08, (74) Agent: MALAMI, Alkisti-Irene; 52 Skoufa St., GR-106 72 Athens (GR).
A01N 1/02, A61K 35/50
- (21) International Application Number: PCT/GR00/00028 (81) Designated States (*national*): AE, AU, BG, BR, CA, CN, CR, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LK, LT, LV, MA, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, YU, ZA.
- (22) International Filing Date: 27 September 2000 (27.09.2000)
- (25) Filing Language: English (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (26) Publication Language: English
- (30) Priority Data: 990100331 29 September 1999 (29.09.1999) GR Published:
— With international search report.
- (71) Applicants and
(72) Inventors: TSAKAS, Spyros [GR/GR]; 2 Mesologiou Sq., GR-116 34 Athens (GR). LINARDOS, Nikolaos [GR/GR]; 7 Kountourioti, GR-145 63 Kifissia (GR).
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CRYOPRESERVED AMNIOTIC HUMAN CELLS FOR FUTURE THERAPEUTIC, DIAGNOSTIC, GENETIC AND OTHERS USES

(57) Abstract: This invention belongs to the field of biotechnology, cryobiology and human therapeutics. Object of the invention are a) amniotic cells originating from amniotic fluid that surrounds the embryo in its early development stages, b) amniotic cells that at early embryonic stage are floating within the human embryo-clone, c) every biological material which will be created directly or indirectly from the above amniotic cells, as well as every biological product or by-product, which will be the outcome of the use of the said cryopreserved amniotic cells, through their reproduction or multiplication under the same or any other modified form and which will possess the same genetic properties and applications. These amniotic cells are isolated from their natural environment and are care preserved in deep-freezing for very long periods of time after their own natural life-span, which is short within their natural environment, that is within the amniotic fluid and within the embryo-clone. The purpose is the genetic and medical use of these cells at a time posterior to their natural destruction. In this way, we succeed to use primal, undifferentiated and genetically identical cells of each human being for diagnosis and therapy of genetic or non-genetic diseases, malfunctions and accidents, where these are known nowadays or shall be applied in the future.

WO 01/23532 A1

TITLE : Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses.

DESCRIPTION

5

Technical field of the invention

The invention refers to the field of biotechnology and more particularly to the field of cryobiology. The invention applies to genetic diagnosis and through this, to genetic therapies of human diseases or life theater accidents by use of already cryopreserved human amniotic cells.

State of the art

Within the amniotic fluid which surrounds the embryo there exist amniotic cells. These cells are biological elements (material) that exist outside of the body and of the development of the embryo. These amniotic cells originate from embryonic cells which are driven away from the embryo during pregnancy, since the early embryonic stages and are moving freely inside the amniotic fluid that surrounds the embryo, where they remain during pregnancy.

20 The amniotic cells are non-differentiated (primal) cells and are genetically identical with all other cells, differentiated or not, of the embryonic body from which they come from. The amniotic cells can easily be grown and multiplied in cell cultures.

25 Until now, the amniotic cells are lost in the environment together with the amniotic fluids at birth and they cannot be used for the embryo's benefit in its future life, which means after birth. Therefore, all humans loose at birth a unique and indispensable genetic material forever.

30 There is no way, under natural conditions, for the amniotic cells to be preserved in a living condition after birth and after the loss of amniotic fluid.

Nowadays, the only known use of amniotic cells is taking place before birth, during pregnancy and is taking place for clearly prenatal testing via amniocentesis.

More specifically, amniotic cells are taken together with amniotic fluid
5 during pregnancy via amniocentesis for the diagnosis of biochemical, cellular, and chromosomal abnormalities of the embryo. During this procedure (Modern Genetics, F.J. Ayala & J.A. Kiger Jr. ed. Benjamin, Cummings, p.p. 722-724), a sample of 10-15ml amniotic fluid that surrounds the embryo is taken by using a surgical syringe between the
10 14 and 16th week of pregnancy. Amniotic cells may also be taken during earlier stages of pregnancy by other means.

Then, the amniotic cells that exist in the amniotic fluid are separated by centrifugation and on them chromosomal number and aberrations are viewed. Besides, other biochemical tests are also performed on the
15 amniotic fluid to see if some known genetic diseases out of the approximately 5000 existing ones are genetically determined in the embryo. Upon the results of this test depends the embryos' life, i.e. the interruption or not of pregnancy.

In the case that the amniotic sample is lost or in cases where more or
20 new material is needed, it is required that a second amniocentesis takes place, if this is allowed by the pregnancy stage.

Object of the invention

The object of the present invention are the amniotic cells, that is cells
25 which exist in the amniotic fluid surrounding the embryo. According to the present invention these cells are isolated from their natural environment and preserved in deep-freezing in a number of samples. Their life span is thus extended longer than their natural life-cycle, for long periods of time, with the goal to multiply and use them in the future for diagnostic,
30 therapeutic and other purposes for the after birth life of the embryo.

Object of the invention are amniotic cells which have been multiplied before their storage, or which have been multiplied after their storage, their thawing and their new cryo-preservation.

It is known that the human body in the different stages of its formation (i.e. embryonic development) and its development cannot be the object of an invention for which a patent may be granted. However, one
5 element (cell) which is isolated from the human body, such as the amniotic cells in the case of the present invention that are isolated by themselves and are flowing freely into the amniotic liquid, with the goal of being destroyed at birth, may represent a patentable invention. This is so, even if the genetic make-up of said the element (the amniotic cell
10 which, according to the invention, has been preserved in a viable-useful state longer than their natural life span) is the same with that of the natural element, that is with the amniotic cell that is part of the amniotic fluid at the time of birth.

15 Technical problem

The existing technical problem, that is solved by this invention is that nowadays, amniotic cells are not preserved in a viable - useful condition after birth, so that they be used in the after-birth life of the embryo and after the amniotic cells' natural destruction.

20

The amniotic cells that are coming from the amniotic fluid have, in comparison to other cells, the following advantage and uniqueness: they are cells that are primary, primal and less differentiated to a great extent, as well as genetically identical to all other cells (differentiated or not) of
25 the embryo's body, from which they originate. Due to these properties the amniotic cells can be the basic material for the production by differentiation of nearly any future differentiated cell of the body, which (differentiated cell) they can substitute genetically, functionally and physiologically. It is thus possible that epidermal cells are produced from
30 amniotic cells for use in plastic surgery.

Under certain conditions, amniotic cells have the prerequisites and the possibility to be differentiated into a number of the 200 existing different human body cells' categories.

Amniotic cells cannot be developed and differentiated by themselves; they have the potential though to be differentiated under specific control lab conditions that are constantly expanding and improving, into categories of differentiated cells that may be of future use to the embryo, that is in its after-birth life.

In the existing technical state of the art, it is not possible for diagnosis of new genetically determined diseases to take place on amniotic cells, besides those that are already known today, due to the non preservation of amniotic cells after birth. For genetic diseases that are already known to science, the only possible diagnosis on amniotic cells is prenatal diagnosis that takes place before birth. However, for diseases that will be known to science in the future, at a stage after the embryo's birth and at any age, it is no longer possible to use amniotic cells for diagnostic purposes in relation to those, because today these cells are lost during birth.

Besides, with the existing technical state of the art, it is not possible to appreciate the genetic predisposition for the development of diseases such as breast cancer, prostate cancer, nor is it possible to appreciate other genetically related genetic diseases like hypertension and heart diseases by using amniotic cells. The genetic cause of these diseases is still unknown, but this might be known in the future, after birth and during life of the human being, whose amniotic cells have been preserved according to the present invention. Thus, for the human being, whose amniotic cells have been preserved after birth, it will be possible at least to diagnose harmlessly genetic diseases.

Amniotic cells are unique cell material that cannot be replaced, which may serve not only for diagnostic purposes, but can also provide the basic cell material for gene and genetic therapy. Under the current state of the art, it is not possible to use amniotic cells for diagnosis or treatment of diseases, the treatment of which is still unknown during birth, or of day life accidents that may take place after birth, as well as of infectious diseases after birth. The reason for this is that following birth,

there do not exist any amniotic cells preserved somewhere for use after birth.

According to the present invention, amniotic cells that are preserved in a viable state after birth offer the possibility to diagnose new genetic diseases and to appreciate the genetic predisposal for the development of diseases, as well as to apply methods of gene or other genetic treatment in the case of genetic relative diseases, accidents and infectious diseases, during each person's life.

Amniotic cells according to the present invention can also be used to produce cells resistant to pathogens, viruses, bacteria, to be used for the creation of new cell lines, for the treatment of wounds, burns, for the addition of tissues for therapeutic or aesthetic reasons.

Another application of the present invention is that it offers the possibility to create healthy cells, tissue and organs from the amniotic cells that are stored and preserved in a viable state. These cells, tissue and organs can be used to replace non-healthy or malfunctioning similar ones and they can also be used to produce genetically identical copies - clones of the person they belong to.

These above mentioned new products, which may have been genetically modified or not, are genetically identical to corresponding cells, tissue and organs of their owner who is the recipient. Therefore, these are compatible with him, which means that when drafted, they have extremely few possibilities to be rejected. For instance, such cells are the muscular cells of cardiac valves, among others.

Due to their preservation according to the present invention, the stored amniotic cells even if contaminated by infection factors such as HIV virus, do have the possibility to be freed by the infection factors by means of specific culture condition. Therefore, they can be used as healthy amniotic cells for therapeutic and other uses thereafter.

Another application of the present invention is that due to the preservation of viable amniotic cells, we may establish a person's

genetic identity (f.e. DNA fingerprint) which may follow the person during his whole future life. The genetic identity may be established when the sample is being taken, or later, after thawing of the preserved cells. Following the existing state of the art, in cases where it is necessary to

5 verify the genetic data of an infant in cases of erroneous information, unwanted adoption or unwanted paternity recognition, as well as of paternity matters for succession, it is necessary to take blood samples from both the father and the child for testing. Because of the present invention, such a new test will not be necessary because each human

10 being may have a ready genetic identity and stored genetic material. The same application is possible also when it is not possible to take a genetic sample in the case of a deceased person, which is necessary for criminology.

Establishing the genetic identity of persons with the use of amniotic cells

15 preserved according to the present invention offers the unique advantage of the creation of collective ready genetic data. This collective data is providing also the potential of unique genetic properties to be discovered and consequently to be used and exploited for research, diagnostic, therapeutic and genetic uses.

20 For example, while a human being was initially a HIV carrier, at a further stage of his life he is becoming virus-free and it is discovered that this is related to the possession of a specific genetic factor, which has been discovered to be the reason for the discard of the virus. By use of the collective genetic data assembled from the establishing of genetic

25 identities it is possible to find out who else possesses the same genetic factor and this in turn may be used for the above purposes.

Another application of the present invention is that amniotic cells that are preserved according to the present invention for uses that will take place after birth, uses in respect to the donor or his next of kin, do own and

30 preserve certain qualities due to the present invention. More specifically, they can be used to create differentiated human cells with much larger probability of success than any other cell category, because they are undifferentiated and genetically related to the recipients.

The stem cells, which are used today with the existing state of the art after being cryopreserved, are coming from the umbilical cord or from bones' marrow tissue. These cells have no relation to the amniotic fluid and what this includes, they are cells more differentiated in comparison to amniotic cells, and due to this differentiation it is relatively more difficult that they be differentiated in other cell categories. Besides, these stem cells also belong to tissues of the embryo, i.e. they are part to the development of the embryo, they differ morphologically and physiologically from amniotic cells and they are used in particular for cancer therapy.

Amniotic cells which are preserved viable and useful for future uses at a time after human birth and which are the object of the present invention, possess due to the present invention certain properties: because they are primal and undifferentiated, they can be used to produce differentiated cell lines of the human body with much greater probabilities of success comparatively to other existing cell categories; they can also be used for detection and therapy of diseases that appear after human birth, i.e. cancer, for genetic engineering and therapy and for curing infectious diseases and accidents that may happen during human life.

One way of taking amniotic cells and separating them from the amniotic fluid for their preservation according to this invention is the following:

During pregnancy, a quantity of amniotic fluid is taken with the amniocentesis process, or in any other way.

1. The amount of amniotic fluid varies between 20 to 80 ml for the needs of the present methodology.
2. The amniotic fluid is properly centrifuged and the amniotic cells are taken from the pellet.
3. The original amniotic cells are cultured by using one of the existing cultures substrates, such as MEM medium.

4. Cryoprotective compounds such as glycerine, DMSO or polyethylene glucols in concentrations between 5 to 50% are added to the amniotic cells.
5. A line of five vial from the start culture is produced and five more lines with 5 vials each, from the rest of the culture, are created by seeding. Thus, we have the first line, which consists of 5 vials on which we are working performing the necessary tests and five more lines, each with five vials, for the deep-freezing process.
6. The temperature of the samples (vials) starts falling via a very sensitive computer controlled system at a pace not more than one degree Celsius (1°C) per min.
7. Ice nucleation process starts by dropping microcrystals of ice so as to create ice from outside the cells, and so as to avoid the creation of crystals within the cells, which will destroy them.
8. Finally the temperature starts dropping faster up to the 150 degrees Celsius below zero (-150°C) and usually the vials are kept in liquid nitrogen (-196°C) where the total of the 25 vials are kept, see original paper of Pentz and Horler. (Pentz S. and Horler H. J. Med. Genet. 1980, Dec. 17 (6) : 472-5).
9. There is a number of thawing processes that are known and that can be applied. In general, the thawing process is nearly a reverse course of the freezing process, where the main consideration is again to avoid ice crystal formation within the cells and the osmotical removal of the cryoprotective compounds of glycerine or DMSO. It has recently been mentioned that even simple exposure to environmental temperature may be equally useful.

The amniotic cells can be prepared for preservation also in other ways, for example using freezing, dehydrating and closing the amniotic cells in polymers or liposomes etc., and then deep-freezing storage takes place as above or at much higher temperatures than that of liquid nitrogen (-196°C).

The amniotic cells' mixture that is being cryopreserved as described above can differ as to the degree of amniotic cells' concentration: from nearly only amniotic cells, up to pure amniotic fluid.

- 5 Freezing processes similar to the above described, are used in early human embryos' deep-freezing during the process of artificial insemination. These embryos are much more sensitive to cryopreservation than amniotic cells, because as they are differentiated and developed they have larger probabilities of being destroyed.

10

In the near future, new, better, simpler and less expensive methods of cryopreservation of amniotic cell will apply.

- The present invention provides the possibility to preserve amniotic cells of human embryos for a long time after birth.
- 15

- One further object of the present invention is the amniotic cells that can be produced during the life-span of a human being, in other words after birth. These amniotic cells can be produced today using adults' mammary gland cells or even epidermal cells.
- 20

- The experiments at Roslin Institute in Scotland have proven that with the nuclear transfer technology from a mammary gland cell to a sheep ovary from where the nucleous had been removed, it is possible to create a viable embryo-clone, Dolly. With an approximately similar technology human embryo-clones may also be produced.
- 25

- It is permitted and legitimately and scientifically acceptable nowadays to produce human clone embryos and to store them up to 14 days of age. It is probable that this time limit will be extended in the future to longer than 14 days, for experimental and medical, genetic.

30

After a human embryo is created in the above way, the said embryos contain inside them in their early stages freely-floating amniotic cells. These early amniotic cells are ignored today for the existing level of state

of the art, that is they are lost after the termination of life of the embryo-clone. There is no way to preserve these amniotic cells in a viable condition under natural circumstances, after the loss of the embryo.

5 The amniotic cells that are taken from the embryo-clone early in its life are necessary for the case that no amniotic cells, that are originating from the amniotic fluid, have been preserved viable after birth, that is in the case that a human loses the opportunity offered by the present invention, in its first object as this is described above.

10 The specific object of the present invention wishes to solve this new technical problem. That is, each individual is given the opportunity to acquire his/her own amniotic cells, that are genetically identical to him/her and are identical to the amniotic cells that he had lost at birth, because his amniotic cells that came from amniotic fluid had not been stored after birth.

15 The amniotic cells that exist free inside the internal part of the early embryo-clone, which can be produced as above for each individual, can be taken easily by using, for example, a micropipette injection under a reverse microscope used for microinjection.

20 After being collected in the above or in another way, the clone's amniotic cells can then be multiplied in cells culture media and then cryopreserved as mentioned earlier for the amniotic cells coming from the amniotic fluid.

25 The process of embryo-clone production should not appear strange to us since already nowadays a huge number of embryos are produced, stored and then abandoned for the needs of artificial insemination.

The present object of the invention, that is the cryopreservation of amniotic cells coming from the embryo-clone at its early stages, has the same applications as the first object of the invention, that is as the
30 cryopreserved amniotic cells that come from the amniotic fluid and are taken during pregnancy.

With its further object, the present invention is offering to living persons the advantage offered to embryos according to its first object, that is the

possibility to preserve their amniotic cells so that these be useful after birth.

Therefore, the present invention offers to all living human beings, to those that are in embryonic stage as well as to those that will be born in the future, the possibility to use their own amniotic cells and to use all the benefits and advantages which genetics, biotechnology and medicine can offer based on their cryopreserved amniotic cells.

A further object of the present invention, is also every biological material which will be produced directly or indirectly from the cryopreserved amniotic cells described above; further object of the present invention is also any biological product or by-product which will be the outcome of reproduction, multiplication or extraction under the same or a modified form by the use of the above described cryopreserved amniotic cells. The said biological material, biological product or by-product will possess the same genetic properties and applications as the cryopreserved amniotic cells described above.

CLAIMS

1. Amniotic cells that are taken from amniotic fluid which surrounds the human embryo at the early stages of its development and that are preserved in a viable and useful state out of their natural environment, after birth and after their natural destruction, by way of their deep-freezing (cryopreservation). These amniotic cells may be :
- 5
- a) multiplied before their cryopreservation, or
 - b) cryopreserved without previously having been multiplied, or
 - 10 c) multiplied after thawing following their cryopreservation and are again cryopreserved for long preservation.
2. Amniotic cells that are taken from human body cells, through the creation from those of embryo – clone, younger or older of the age of 14 days. These amniotic cells are isolated from their natural environment and are preserved, through their cryopreservation, in a viable – useful state after the end of the life of the embryo – clone. These amniotic cells may be:
- 15
- d) multiplied before their cryopreservation, or
 - 20 e) cryopreserved without previously having been multiplied, or
 - f) multiplied after thawing following their cryopreservation and are again cryopreserved for long preservation.
3. Compositions which contain a) a number of amniotic cells according to each of claims 1 and 2 in different concentrations, starting from pure amniotic cells up to pure amniotic fluid, as well as b) compounds which make the amniotic cells able for long cryopreservation, such compounds being glycerin, or dimethylsulfoxide (DMSO), or polyethylene glycols (PEG's).
- 25
- 30
4. Amniotic cells according to each of claims 1, 2 and 3, which at a point in time posterior to their natural loss and destruction are used at any time :

- a) for genetic, diagnostic and therapeutic reasons.
- b) for the application on them of genetic identification.
- c) for establishing any kind of genetic identities data (such as DNA fingerprint) for diagnostic, therapeutic, social, legal, succession,
5 criminological and other purposes.

5. Amniotic cells according to claim 4, that offer a collective ready sample of genetic material and offer the possibility to identify unique genetic properties and their use and exploitation for research, diagnostic,
10 therapeutic, genetic and commercial purposes.

6. Amniotic cells according to claims 1 to 5 that are used for:
- a) on-time diagnosis and therapy of genetic diseases or genetic predisposition to diseases or functional failures,
 - 15 b) gene therapy, or for their differentiation in cells, tissues and organs for substituting the ones which suffer failures,
 - c) therapy from diseases or accidents, for the creation of cell lines resistant to pathogens, viruses, bacteria, for the creation of new cell lines, for the healing of wounds, burns, for the addition of tissues for
20 therapeutic or cosmetic purposes.

7. Amniotic cells according to claims 1, 2, 4 and 6 that are useful for the creation of differentiated cell lines categories, from the approximately two hundred (200) existing ones in the human body.
25

8. Amniotic cells according to claims 1, 2, 6 and 7, that are used through cultures to produce tissues and in the future to produce organs or even genetic clones of their owner.

30 9. Biological compound, which will be directly or indirectly produced from amniotic cells according to claims 1, 2, 5, 6, 7 and 8, as well as any biological product or by-product which will be produced from the use of such cryopreserved amniotic cells through their reproduction or

multiplication, under the same or under different form, and which possesses the same genetic properties and applications as them.

INTERNATIONAL SEARCH REPORT

Intel 3 Application No

PCT/GR 00/00028

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/08 A01N1/02 A61K35/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE, LIFESCIENCES, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PENTZ S & HÖRLER H: "A cryopreservative procedure for storing cultivated and uncultivated amniotic fluid cells in liquid nitrogen" JOURNAL OF MEDICAL GENETICS, vol. 17, 1980, pages 472-475, XP000971555 cited in the application the whole document	1-8
X	NIERMEIJER M F ET AL: "Transport and storage of amniotic fluid samples for prenatal diagnosis of metabolic diseases." HUMANGENETIK, vol. 20, no. 2, 1973, pages 175-178, XP000971556 the whole document	1-8

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

4 January 2001

Date of mailing of the international search report

15/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

INTERNATIONAL SEARCH REPORT

Intel. Application No
PCT/GR 00/00028

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCAGGIANTE B ET AL: "Impianto di cellule epiteliali amniotiche umane crioconservate in un soggetto affetto da malattia di Niemann-Pick tipo B 'Graft of cryopreserved human amniotic epithelial cells in a subject with type B Niemann-Pick disease! " PEDIATRIA MEDICA E CHIRURGICA, vol. 9, no. 1, January 1987 (1987-01) - February 1987 (1987-02), pages 89-92, XP000971552 page 90	1-8
X	WO 97 35472 A (ADVANCED REPRODUCTION TECHNOLO) 2 October 1997 (1997-10-02) page 9, line 12 -page 10, line 10	1-8
A	US 5 879 937 A (RONCAROLO MARIA-GRAZIA) 9 March 1999 (1999-03-09)	
A	EP 0 333 328 A (GENETHICS LTD) 20 September 1989 (1989-09-20)	
A	EP 0 815 867 A (SRL INC) 7 January 1998 (1998-01-07)	
A	KIND A & COLMAN A: "Therapeutic cloning: Needs and prospects" SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, vol. 17, no. 3, June 1999 (1999-06), pages 1171-1174, XP000971596	
E	WO 00 73421 A (PRESTIDGE PETER D ;WIGGINTON GORDON (GB); GOLDSTEIN ALLAN L (US);) 7 December 2000 (2000-12-07) page 3 -page 6	1-8

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 9

Present claim 9 relates to a compound defined by reference to its origin, namely human amniotic cells. The claim covers all compounds which can be extracted or produced from such source, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for no specific compound. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search was performed for claim 9.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter Application No

PCT/GR 00/00028

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9735472	A	02-10-1997	US 5897987 A CA 2250084 A EP 0891134 A JP 2000507547 T	27-04-1999 02-10-1997 20-01-1999 20-06-2000
US 5879937	A	09-03-1999	US 5405751 A	11-04-1995
EP 0333328	A	20-09-1989	AT 98111 T AU 3218389 A AU 640609 B CA 1330418 A DE 68911178 D ES 2060750 T WO 8907425 A US 5612028 A	15-12-1993 06-09-1989 02-09-1993 28-06-1994 20-01-1994 01-12-1994 24-08-1989 18-03-1997
EP 0815867	A	07-01-1998	AU 1319797 A WO 9726902 A	20-08-1997 31-07-1997
WO 0073421	A	07-12-2000	NONE	